Interestingly, a significant proportion of patients who achieved marked clinical improvement (achieving at least a 75% reduction in the clinical severity score of AD from the baseline) after anti-OX40 antibody therapy for 36 weeks experienced prolonged clinical improvement for more than 20 weeks after discontinuation of the therapy [115]. The gene discussed is TNFRSF4; the disease is Alzheimer disease.